SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) and VisionRenu Biomedical Technology Co., Ltd. have announced the signing of a Strategic Memorandum of Understanding (MOU) to collaborate in AI-powered biotechnology, precision medicine, and international capital market initiatives. The agreement, announced on June 29, 2026, establishes a framework for combining SUIC's expertise in business acceleration and capital market access with VisionRenu's specialization in brain health and ophthalmic medical devices.
Under the MOU, the companies will work together to drive global commercialization and expansion. VisionRenu, based in Taiwan, brings its flagship MagRenu® Transcranial Magnetic Stimulation (TMS) System, approved by Taiwan's TFDA for depression treatment, along with proprietary ophthalmic laser technologies. SUIC, a technology-enabled investment and business acceleration company, will provide strategic financing, business development, and potential U.S. capital market opportunities. The collaboration is intended to accelerate VisionRenu's global expansion while creating long-term value through innovation and sustainable growth.
The partnership positions both companies to enter the rapidly growing AI biotechnology sector. Artificial intelligence is reshaping biotechnology by accelerating gene editing, DNA synthesis, precision medicine, and digital biology. AI enables faster discovery of disease-related genes, improves CRISPR gene-editing precision, optimizes DNA and protein design, and shortens development cycles for next-generation therapeutics. Combined with automated DNA synthesis and robotic laboratories, AI is transforming biological research through the Design-Build-Test-Learn (DBTL) platform.
Industry analysts expect AI-enabled biotechnology to become one of the world's largest innovation markets over the coming decades, creating multi-trillion-dollar opportunities across healthcare, drug discovery, synthetic biology, advanced manufacturing, and sustainable materials. SUIC's strategic collaboration with VisionRenu, together with partnerships involving AI biotechnology startups supported by Taiwan's Ministry of Health and Welfare (MOHW), positions the Company to expand into this growing sector.
The agreement is the first step toward building a long-term strategic partnership. Both companies view this MOU as a foundation for leveraging AI, precision medicine, gene technologies, and international capital market resources to accelerate innovation and build long-term shareholder value. For more information about VisionRenu, visit https://www.vision-renu.com/. For more information about SUIC, visit https://sinounitedco.com/.
